IP trouble defers launch of Novo's long-acting hemophilia therapy
Long-acting hemophilia therapy Esperoct has won FDA approval, but US patients will have to wait until next year to access it, in a blow for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
